Clinical Trial Update: Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating switching from an LHRH agonist to an LHRH antagonist for progressive castration-resistant prostate cancer; the current …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: British Columbia Cancer Agency | Conditions: Prostate Neoplasm | Phase 2 | Status: UNKNOWN